Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ocular drug development--future directions.

David Sherris1

  • 1Sherris Pharma Partners, 37 Neillian Crescent, Jamaica Plain, MA 02113, USA. dsherris@sherrispharma.com

Angiogenesis
|March 21, 2007
PubMed
Summary

Advances in anti-angiogenic therapies are revolutionizing treatments for ocular neovascular diseases like age-related macular degeneration and diabetic retinopathy. Future treatments will likely involve broader-acting agents and synergistic combinations.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Facelift Demand Among Patients Using Glucagon-Like Peptide-1 Receptor Agonists: The Impact of Weight Loss-Associated Facial Changes.

Facial plastic surgery & aesthetic medicine·2026
Same author

Nationwide Adherence to Bell's Palsy Clinical Practice Guidelines: Retrospective Analysis Using a Large-Scale EHR Database.

Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery·2026
Same author

RETRACTED: Gravina et al. The Brain Penetrating and Dual TORC1/TORC2 Inhibitor, RES529, Elicits Anti-Glioma Activity and Enhances the Therapeutic Effects of Anti-Angiogenetic Compounds in Preclinical Murine Models. <i>Cancers</i> 2019, <i>11</i>, 1604.

Cancers·2025
Same author

RETRACTED: The Brain Penetrating and Dual TORC1/TORC2 Inhibitor, RES529, Elicits Anti-Glioma Activity and Enhances the Therapeutic Effects of Anti-Angiogenetic Compounds in Preclinical Murine Models.

Cancers·2019
Same author

Characterization of Small Molecules Inhibiting the Pro-Angiogenic Activity of the Zinc Finger Transcription Factor Vezf1.

Molecules (Basel, Switzerland)·2018
Same author

The Novel mTOR Complex 1/2 Inhibitor P529 Inhibits Human Lung Myofibroblast Differentiation.

Journal of cellular biochemistry·2017

Area of Science:

  • Ophthalmology
  • Vascular Biology
  • Pharmacology

Background:

  • Ocular neovascular diseases, including age-related macular degeneration (AMD) and diabetic retinopathy (DR), represent a significant unmet medical need with large patient populations.
  • Despite available research-level technologies, pharmaceutical and biotech industries were slow to develop clinical treatments for these conditions.
  • Recent years have seen a surge in business development deals, primarily focusing on vascular endothelial growth factor A (VEGF-A) targeted therapies.

Purpose of the Study:

  • To highlight the technological advancements in treating retinal neovascularization.
  • To underscore the growing market and clinical interest in ocular therapeutics.
  • To forecast future directions in the development of treatments for neovascular eye diseases.

Main Methods:

  • Review of technological progress in anti-angiogenic agents for ocular diseases.
  • Analysis of market trends and business development deals in the pharmaceutical and biotech sectors.
  • Examination of the prevalence and progression of AMD and DR.

Main Results:

  • Significant market potential exists for treatments targeting AMD and DR, affecting millions in the US alone.
  • The past three years have witnessed substantial investments in VEGF-A targeted therapies.
  • There is a clear shift towards developing novel ocular drugs to combat neovascularization.

Conclusions:

  • Anti-VEGF-A therapies are a major advancement, but the next wave of ocular treatments will likely involve agents with broader activity or synergistic effects.
  • Future drug development will focus on targeting later stages of the angiogenic pathway and combination therapies.
  • This evolving landscape is expected to drive further significant business development in the field of ocular neovascular diseases.

Related Experiment Videos